Luteinized unruptured follicle (LUF) syndrome is a recurrent anovulatory dysfunction that affects up to 23% of women with normal menstrual cycles and up to 73% with endometriosis. Mechanisms underlying the development of LUF syndrome in mares were studied to provide a potential model for human anovulation. The effect of extended increase in circulating LH achieved by administration of recombinant equine LH (reLH) or a short surge of LH and decrease in progesterone induced by prostaglandin F 2 a (PGF 2 a) on LUF formation (Experiment 1), identification of an optimal dose of COX-2 inhibitor (flunixin-meglumine, FM; to block the effect of prostaglandins) for inducing LUFs (Experiment 2), and evaluation of intrafollicular endocrine milieu in LUFs (Experiment 3) were investigated. In Experiment 1, mares were treated with reLH from Day 7 to Day 15 (Day 0Zovulation), PGF 2 a on Day 7, or in combination. In Experiment 2, FM at doses of 2.0 or 3.0 mg/kg every 12 h and human chorionic gonadotropin (hCG) (1500 IU) were administered after a follicle R32 mm was detected. In Experiment 3, FM at a dose of 2.0 mg/kg every 12 h plus hCG was used to induce LUFs and investigate the intrafollicular endocrine milieu. No LUFs were induced by reLH or PGF 2 a treatment; however, LUFs were induced in 100% of mares using FM. Intrafollicular PGF 2 a metabolite, PGF 2 a, and PGE 2 were lower and the ratio of PGE 2 :PGF 2 a was higher in the induced LUF group. Higher levels of intrafollicular E2 and total primary sex steroids were observed in the induced LUF group along with a tendency for higher levels of GH, cortisol, and T; however, LH, PRL, VEGF-A, and NO did not differ between groups. In conclusion, this study reveals part of the intrafollicular endocrine milieu and the association of prostaglandins in LUF formation, and indicates that the mare might be an appropriate model for studying the poorly understood LUF syndrome.
Introduction
Anovulation is one of the main causes of infertility in women and females of many domestic species. One of the types of anovulatory dysfunction is luteinized unruptured follicle (LUF) syndrome, which has been reported in women (Marik & Hulka 1978 , Koninckx et al. 1981 , Hamilton et al. 1985 , Hulka 1985 , Katz 1988 , Check 2007 , mares (Kaiser et al. 1999 , Gastal et al. 2006 , Ginther et al. 2007a , Cuervo-Arango & Newcombe 2009 ), cattle (Peter 2004 , llamas (Adams et al. 1991) , rhinoceroses (Stoops et al. 2004) , and elephants (Lueders et al. 2011) . LUFs, also known as hemorrhagic anovulatory follicles (HAFs) in veterinary medicine, occur when the preovulatory follicle fails to rupture or ovulate and the antrum gets increasingly filled with blood. LUF/HAF is the most common form of anovulation in mares. LUF syndrome during the breeding season is considered a serious economic concern for the equine industry. Similarly, anovulation can have significant financial implications for women undergoing assisted reproductive techniques (Eijkemans et al. 2005) . Therefore, it is important to investigate the mechanisms of development of LUF syndrome. Greater knowledge about the pathophysiology of LUFs can be applied to prevent their occurrence and thus to develop safe and effective treatments to optimize reproductive health in both animals and humans.
The ultrasonographic morphological characteristics of naturally occurring or induced LUFs are similar in women (Priddy et al. 1990 , Zaidi et al. 1995 and mares (Coetsier & Dhont 1996 , Cuervo-Arango & Newcombe 2012 . LUF formation involves the
Besides mediating maternal-foetal exchange throughout gestation, the placenta plays a major role in orchestrating maternal adaptation to pregnancy by secreting a variety of steroid and peptide hormones. These placental hormones stimulate maternal physiological changes that are essential for pregnancy success. The placenta is unique in several ways. First, although the placenta is a shared organ between mother and foetus, it is an extraembryonic tissue and is therefore primarily regulated by the foetal genome. Secondly, the placenta separates from mother and foetus after birth, making it a truly transient organ. For these reasons, the epigenetic mechanisms involved in placental development and regulation of gene expression within this tissue may not be subject to the same lifetime epigenetic constraints as other organs that must function throughout an individual's life.
In humans, from implantation of the blastocyst, the placenta invades the decidua colonizing and transforming the uterine spiral arterioles to sequester a maternal blood supply for efficient maternalfoetal exchange (Roberts 2010) . Invading placental extravillous cytotrophoblasts employ molecular mechanisms that closely match those of a metastatic tumour (Murray & Lessey 1999) ; however, although this process is strictly controlled both spatially and temporally in the placenta, it is somewhat dysregulated in cancer. Such mechanisms are not fully understood but include complex interactions between both extravillous cytotrophoblasts and maternal endothelium and leucocytes (Graham & Lala 1992 , Lyall 2002 , Yu et al. 2015 . Emerging evidence suggests that epigenetic regulation of the placental transcriptome is important for the molecular control of placental growth and differentiation. This review highlights some of the complexities of placental DNA methylation in humans and how this process may be disrupted in some pregnancy pathologies. The focus of this review is genome-wide DNA methylation studies on human placental tissues, what we have learnt from these studies and what remains to be discovered.
Epigenetics
Epigenetics is often defined as modifications that affect genome architecture and accessibility which can influence gene transcription, without altering the underlying DNA sequence. Such modifications include DNA methylation and histone modifications that, unlike changes to the DNA sequence, may be reversible. This review focuses on the most widely studied epigenetic modification: DNA methylation, which is the addition of a methyl group (-CH 3 ) to cytosine bases, is a process catalyzed by DNA methyltransferases (DNMT1, DNMT3A and DNMT3B). DNMT1 maintains and repairs established DNA methylation, whereas DNMT3A and DNMT3B are involved in de novo DNA methylation (Goll & Bestor 2005 , Denis et al. 2011 . Typically, DNA methylation of gene regulatory regions is associated with repression of gene expression; however, many genome-wide DNA methylation studies have demonstrated that this is not always the case (Ke et al. 2010 , Moarii et al. 2015 , Becket et al. 2016 . DNA methylation is important in genomic imprinting and X chromosome inactivation in females. It has been widely studied in diseases and has been used as a biomarker for predicting disease or environmental exposures (Portela & Esteller 2010) .
DNA methylation in the placenta
DNA methylation plays a crucial role during cellular differentiation and development . Studying DNA methylation in the placenta is complicated by the presence of several different cell types. The majority of studies investigating this topic have used chorionic villi, which have a different DNA methylation profile than embryonic tissues, the maternal decidua or foetal membranes (amnion and chorion) (see Robinson & Price 2015) . Chorionic villi are the site of maternal-foetal exchange and hormone production and contain a mixture of cell types with cells derived from both the trophectoderm and the inner cell mass. The cellular composition of individual placentas varies and this is most apparent in the presence of a pregnancy complication (Mayhew et al. 2004 ).
Hypomethylation of placental tissue
It has been known for some time that the genome of the placenta is hypomethylated compared with that in other healthy tissues (Ehrlich et al. 1982 , Fuke et al. 2004 ). However, how or why the placental genome is hypomethylated remains unclear, but may reflect the heterogeneous nature of placental tissue and the corresponding different DNA methylation profiles of distinct cell populations. Shortly after fertilization, the embryonic DNA becomes largely demethylated (Smith et al. 2012) . In the following days, the cells in the inner cell mass rapidly undergo de novo DNA methylation but the trophectoderm remains hypomethylated (reviewed in Robinson & Price 2015) . However, this information has been obtained in the extensively and easily studied mouse model. Dissecting out the DNA methylation profiles in different cell types across development in human embryos is technically more difficult than in mice. Some data suggest that DNA methylation throughout embryo development in humans differs when compared with mice (Guo et al. 2014 ). Furthermore, it appears that the DNA methylation levels in the trophectoderm are marginally lower than those in the inner cell mass in humans, but these findings are based on observations in very few samples (Guo et al. 2014) .
The chorionic villi of the placenta are composed of cells derived from both the trophectoderm (all populations of trophoblasts) and the inner cell mass (extra-embryonic mesoderm and endoderm progenitors comprising the villous stroma and blood vessels). The villous syncytiotrophoblast is the major cell type in the placenta and is derived from the trophectoderm via the villous cytotrophoblasts which fuse to form the syncytium (Gude et al. 2004) . Therefore, hypomethylation of the placental genome may reflect the maintenance of the early hypomethylated state of the trophectoderm through development. It is also known that DNMT1 expression in the placenta is reduced with mono-allelic DNA methylation of the promoter region (Novakovic et al. 2010 , Das et al. 2013 , which may also contribute to the hypomethylated state of the placental methylome.
Partially methylated domains in the placenta
Hypomethylation within the placenta is not uniform but occurs in large domains (>100 kb) called partially methylated domains (PMDs) which are regions of reduced DNA methylation that cover approximately 40% of the placental genome . PMDs are unique to a few different tissue types that include the placenta, some cultured cells and cancer (Lister et al. 2011 , Schroeder & LaSalle 2013 . Genes within placental PMDs are typically repressed, have tissue-specific functions and their methylation status is maintained throughout gestation ). However, even though PMDs seem to be a characteristic trait of the placental methylome, the majority of studies published to date have largely ignored them; therefore, it remains unclear why the placental methylome is characterized by PMDs. It is also yet to be determined when PMDs are first established in the trophoblast or placenta, what roles PMDs and the genes located within them play and whether they are disrupted in pregnancy complications.
Foetal sex differences in DNA methylation
Although the placental genome contains fewer methylated cytosines than other tissues (Ehrlich et al. 1982 , Fuke et al. 2004 ), a large study in 248 placentas has shown that there is a large range of DNA methylation of 2 - 5% (Dwi Putra et al. 2014 ), but the reason for this variation requires further investigation. The regions with reduced DNA methylation included long interspersed nuclear elements (LINE1) and Alu repeats, as well as CpG island promoters associated with X-linked genes (Cotton et al. 2009 ). By using an Illumina DNA methylation microarray, Cotton et al. (2009) assessed 84 sites within X chromosome-associated promoter CpG islands and found that overall DNA methylation of these sites was reduced in female placentas to a greater extent than in male placentas, suggesting that there was DNA methylation loss at the inactive X chromosome. This was further supported by pyrosequencing assays for CpG island-associated promoters on the X chromosome (Cotton et al. 2009 ).
Our comparison of DNA methylation across 8346 CpG sites on the X chromosome using three datasets of placental tissue from uncomplicated term pregnancies (GSE44667, GSE54399 and GSE57767) , Anton et al. 2014 including 22 female and 19 male placentas indicated that the X chromosome from female placentas was more methylated than the X chromosome from male placentas (unpaired t-test, mean (female) = 0.432; mean (male) = 0.389, P-value = 9.552e-08) (Fig. 1) . When only the CpG sites within the 5′-UTR were analysed (2512 probes), DNA methylation on the X chromosome was higher in females than in males, as expected and seen for other organs (Yasukochi et al. 2010 , Cotton et al. 2011 , Hall et al. 2014 , Joo et al. 2014 .
Cell-type differences in DNA methylation
As previously mentioned, the placenta is composed of several different cell types (Kanellopoulos-Langevin et al. 2003) that are likely to have their own unique corresponding methylome. Grigoriu et al. (2011) compared DNA from whole placenta with corresponding isolated fibroblasts and cytotrophoblasts separated from the same tissues using an enzymatic and magnetic bead separation methodology. By comparing DNA methylation profiles using the Illumina Infinium Human Methylation 27K BeadChip Array, the authors were able to identify 61 probes for genomic regions that were differentially methylated between whole placenta and cytotrophoblasts, 315 between whole placenta and fibroblasts and 442 between fibroblasts and cytotrophoblasts (Grigoriu et al. 2011) . Interestingly, the cytotrophoblast DNA methylation profiles clustered with the whole placenta samples and the fibroblasts clustered on their own (Grigoriu et al. 2011) . These results indicate that the methylome differs between the different cell types that make up the placenta and that this should be considered when performing DNA methylation studies in this organ. This is supported by other studies that have shown differential DNA methylation changes in distinct placental cell populations (Novakovic et al. 2008 (Novakovic et al. , 2011a .
Besides 5-methylcytosine, there are other derivatives, such as 5-hydroxymethylcytosine, that arise from the oxidation of 5-methylcytosine in the process of DNA demethylation (Hernando-Herraez et al. 2015) .
Figure 1
DNA methylation is higher on the X chromosome in placentas from female bearing pregnancies. DNA methylation levels were assessed at 8346 CpG sites on the X chromosome. DNA methylation of placental tissue from three publicly available data sets (GSE44667, GSE54399 and GSE57767) for a total of 19 male and 22 female term uncomplicated placentas was assessed. Probes that had missing values for samples were discarded, leaving 8346 X chromosome probes for all samples. Normalization was performed using the beta-mixture quantile normalization (BMIQ) method, which corrects for the two different designs of probes, followed by quantile normalization (Teschendorff et al. 2013) . Batch effects were corrected using the Combat function implemented in the ChAMP Bioconductor package (Leek et al. 2012 , Morris et al. 2014 . Sample sex was identified using the minfi package in which the median value of the β values for probes that mapped uniquely for the X and Y chromosome, respectively, were first determined (Aryee et al. 2014) . This resulted in the identification of 19 male and 22 female placentas. The overall DNA methylation for the X chromosome in each sample was calculated by taking the overall mean β value of all the probes that map to the X chromosome. Identified 22 differentially methylated loci that are associated with SGA
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The precise role and function of 5-hydroxymethylcytosine require further study; however, it is important in development and disease (Tan & Shi 2012) . In a recent study by Fogarty et al. (2015) , differences in the levels of 5-methylcytosine and 5-hydroxymethylcytosine between syncytiotrophoblast and cytotrophoblasts were assessed using immunohistochemical quantification (Fogarty et al. 2015) . This study showed higher levels of 5-methylcytsoine in cytotrophoblasts, whereas 5-hydroxymethylcytosine was more abundant in syncytiotrophoblast (Fogarty et al. 2015) . The biological reason behind this difference is unclear but suggests that the methylomes may vary substantially between the different cell types that make up the placenta, which may be consistent with the differentiation state of the two villous trophoblast populations. The extent to which these epigenetic differences influence and define different cell populations in the placenta remains to be elucidated.
DNA methylation changes across gestation
One of the first studies to characterize DNA methylation across gestation used HPLC to show that global DNA methylation levels increase with gestational age (Fuke et al. 2004 ), which has been subsequently confirmed by others using different methodologies (Novakovic et al. 2011b , Price et al. 2012 . Novakovic et al. (2011b) used Illumina arrays to show that DNA methylation increases from first trimester to third trimester with levels of DNA methylation very similar between second and third trimester. The authors suggest that the change in cell composition and differentiation of cells that occurs as gestation progresses may contribute to these differences, as well as the bias of this methodology with respect to the actual methylation sites assessed by the array probes (Novakovic et al. 2011b ).
DNA methylation changes and pregnancy complications
The analysis of the placental methylome in pregnancy complications such as pre-eclampsia (PE), intrauterine growth restriction (IUGR), preterm birth (PTB) and gestational diabetes mellitus (GDM) has largely been performed using Illumina Infinium Human Methylation BeadChip Arrays (Banister et al. 2011 , Lambertini et al. 2011 , Jia et al. 2012 , Ruchat et al. 2013 , Anton et al. 2014 , Chu et al. 2014 , Liu et al. 2014 , Petropoulos et al. 2014 (Table 1) . These studies identify differential methylation between placentas from controls and the pregnancy complication under investigation, with some studies showing overlap of differentially methylated sites in umbilical cord blood (Ruchat et al. 2013 . However, Hillman et al. (2015) found no differences in DNA methylation in placenta, but observed differences in cord blood when comparing IUGR with controls. Interestingly, these differences in DNA methylation profiles in cord blood between healthy pregnant women and women diagnosed with pregnancy complications have also been reported in a preliminary study between healthy women and women diagnosed with either PE or PTB using maternal peripheral blood sampled at 15-week gestation, long before their diagnosis (Bianco-Miotto et al. 2015) . Comparison between studies is made difficult due to different methodologies used; however, for studies in which comprehensive gene lists were available, we compared the overlap in differentially methylated genes. For GDM compared with uncomplicated pregnancies, we were able to compare two studies , Petropoulos et al. 2014 and found 91 genes that overlapped between the two studies. For PE, there appeared to be much less overlap with only two genes (DAPK3, PAPPA2) in common between the two studies that were compared , Chu et al. 2014 . This is not surprising as Blair et al. (2013) assessed samples from women with early-onset pre-eclampsia and compared them with samples from gestational agematched controls, whereas Chu et al. (2014) assessed samples from women with PE including 15 of 24 from women with term pre-eclampsia and compared them with term controls (Chu et al. 2014) . Term PE has a very different aetiology to early-onset disease and preterm controls, although matched for gestational age could not be considered to be uncomplicated pregnancies (Andraweera et al. 2012) . Despite this, Chu et al. (2014) found only one gene to be differentially methylated in early-onset versus term PE. Of particular interest, only one study thus far has examined DNA methylation using methylC-seq ), but was hampered by a small sample size (just three term placenta samples). MethylCseq ) uses sodium bisulphite treatment to convert all non-methylated cytosines to thymine, allowing single-base pair resolution of all 5mC sites within a sample. With sufficient coverage using high-throughput sequencing, the entire 5mC methylome can be identified in one methylC-seq library. This protocol is in stark contrast to the predominant use (driven by cost) of DNA methylation microarrays, which cover only ~1 - 2% of the genome (Plongthongkum et al. 2014) . Consequently, the majority of the placental methylome remains unexplored. This shortcoming is further compounded by the lack of studies quantifying both DNA methylation and gene expression in matched samples, which is crucial in linking altered DNA methylation to changes in gene regulation. There are few studies that have assessed gene expression and DNA methylation in the same samples and both of these only studied the term placenta (Turan et al. 2012 . Without investigating gene expression together with DNA methylation, it is difficult to elucidate the role of DNA methylation in gene regulation in the placenta and how this may be disrupted in pregnancy complications. With reducing costs for next-generation sequencing, we anticipate more genome-wide placental DNA methylation studies in the future, which would increase our knowledge of placental DNA methylation and its effects on gene transcription in health and disease.
Conclusion
Although there are several studies of genome-wide DNA methylation profiling in the human placenta, our knowledge remains insufficient to draw well-supported conclusions about the role of DNA methylation in placental development, particularly since most studies have very small sample sizes. There are currently very few whole-genome bisulphite sequencing studies that provide comprehensive profiles of placental DNA methylation across gestation, and how these epigenetic modifications correlate with gene expression. What is also unclear is the role of other epigenetic modifications such as 5-hydroxymethylation and histone modifications in placental gene regulation. An integrated analysis of the placental epigenomic landscape may be required to begin elucidating the role of the placental epigenome in normal development and in pregnancy complications. Finally, as recently highlighted (Robinson & Price 2015) , without understanding the distinct methylation profiles of the different cell types that make up the placenta, it is difficult to understand the role of DNA methylation in healthy placentas and what changes accompany pathology.
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